Comparative effectiveness and safety of tenecteplase versus alteplase for intravenous thrombolysis in acute ischemic stroke: a retrospective study.

ABSTRACT:

Background

Tenecteplase has been proposed as a practical alternative to alteplase for intravenous thrombolysis in acute ischemic stroke. Although randomised trials have demonstrated noninferiority, data from real-world comparative cohorts remain limited.

Aim

This study evaluated functional and safety outcomes of tenecteplase compared with alteplase in a single-center cohort.

Methods

We retrospectively analysed consecutive patients with acute ischemic stroke who underwent intravenous thrombolysis with either tenecteplase or alteplase between April 2023 and April 2025. The primary endpoint was excellent functional recovery at 90 days, defined as a modified Rankin Scale (mRS) score of 0-1. Secondary endpoints included functional independence (mRS 0-2), early neurological

SUBMITTER: Zhao W 

PROVIDER: S-EPMC12554612 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature